Copyright
©The Author(s) 2024.
World J Hepatol. Feb 27, 2024; 16(2): 211-228
Published online Feb 27, 2024. doi: 10.4254/wjh.v16.i2.211
Published online Feb 27, 2024. doi: 10.4254/wjh.v16.i2.211
Figure 3 The cumulative incidence of study outcomes in the acute phase vs post-acute phase of infection.
A: Hepatocellular carcinoma; B: All-cause mortality; C: Adverse hepatic outcomes; D: Palliative care. HCC: Hepatocellular carcinoma; COVID-19: Coronavirus disease 2019.
- Citation: Mak LY, Chung MSH, Li X, Lai FTT, Wan EYF, Chui CSL, Cheng FWT, Chan EWY, Cheung CL, Au ICH, Xiong X, Seto WK, Yuen MF, Wong CKH, Wong ICK. Effects of SARS-CoV-2 infection on incidence and treatment strategies of hepatocellular carcinoma in people with chronic liver disease. World J Hepatol 2024; 16(2): 211-228
- URL: https://www.wjgnet.com/1948-5182/full/v16/i2/211.htm
- DOI: https://dx.doi.org/10.4254/wjh.v16.i2.211